Bermekimab Biosimilar - Research Grade

Human

IL1A

>1mg/ml

IgG1 - kappa

CHO Cells

Vilamakitug Biosimilar - Research Grade (ICH5284)

https://www.imgt.org/mAb-DB/

ICH3002

P01583

Blue ice

This product is a research-grade biosimilar of bermekimab (development codes MABp1; originator trade name Xilonix), supplied as an unconjugated, non-therapeutic analog built around the interleukin-1 alpha (IL-1A) target. It is offered for research use only and is not a clinical drug. Bermekimab is a fully human IgG1, kappa monoclonal antibody that binds the alarmin cytokine IL-1 alpha with high affinity and neutralises its biological activity, thereby preventing IL-1 alpha from engaging its receptor and driving sterile inflammation. The originator has been evaluated across advanced solid tumours (colorectal and pancreatic cancer), atopic dermatitis, and hidradenitis suppurativa, where IL-1 alpha-driven inflammation is implicated. This biosimilar reproduces the target specificity and human IgG1/kappa framework of the reference molecule so investigators can use it as a comparator, control, or tool reagent in functional assays. It is manufactured to research-grade endotoxin standards and available in bulk milligram-to-gram quantities. As a human-target biosimilar it is intended for in-vitro and functional characterisation rather than routine mouse in-vivo dosing. All statements are guidance for ichorbio to review. Interleukin-1 alpha (IL-1A; UniProt P01583) is a pleiotropic cytokine of the IL-1 family that bridges innate and adaptive immunity. It has a distinctive dual biology: constitutively present intracellularly, it can act in the nucleus, and upon cell damage or necrosis it is released as an alarmin that signals danger to the surrounding tissue, initiating sterile (non-infectious) inflammation. Secreted or membrane-associated IL-1 alpha binds the type I IL-1 receptor (IL1R1) together with the accessory protein IL1RAP, forming a high-affinity complex that activates NF-kB and the p38, ERK (p42/p44), and JNK MAPK pathways. This drives downstream pro-inflammatory gene expression. IL-1 alpha is implicated in tumour-associated inflammation, cardiovascular disease, and inflammatory skin conditions, making it an attractive therapeutic and research target for neutralising antibodies such as bermekimab.

IL-1 alpha, Hematopoietin-1, Interleukin-1 alpha, IL1F1

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks